Skip to content

Evaluation the efficacy of D-Chiro-Inositol in endometriosis

Evaluation the efficacy of D-Chiro-Inositol in pain relif in endometriosis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230111057113N1
Enrollment
60
Registered
2023-02-23
Start date
2023-02-21
Completion date
Unknown
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis is characterized by the presence of endometrial and stromal tissue outside the uterine cavity. Endometriosis

Interventions

Intervention 1: Intervention group: two tablets containing 1200 mg of DCI and 120 mg of alpha-lactalbumin for the first month and 600 mg of DCI and 60 mg of alpha-lactalbumin for the next 5 months. I

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age between 20 and 40 years old Diagnosis of endometriosis Refusal to use other standard therapies Systemic estradiol >90 pg/ml during the first 4 days after the end of menstrual cycle. informed consent to entry Pelvic pain that has been present for at least three months

Exclusion criteria

Exclusion criteria: Diagnosis of secreting tumors previous history of Diabetes Melitus BMI>30 Taking hormones or inositol within 6 months before starting the study Using other drugs, especially (OCP and...) Any disease that interferes with the use of D-chiroinositol

Design outcomes

Primary

MeasureTime frame
Pelvic pain. Timepoint: At the beginning of the study, one month after the start of treatment, 6 months after the start of treatment. Method of measurement: VAS score.

Secondary

MeasureTime frame
Pelvic pain. Timepoint: At the beginning of the study, one month after the start of treatment, 6 months after the start of treatment. Method of measurement: VAS score.;Dyspareunia. Timepoint: At the beginning of the study, one month after the start of treatment, 6 months after the start of treatment. Method of measurement: Vas score.;Dysmenorrhea. Timepoint: At the beginning of the study, one month after the start of treatment, 6 months after the start of treatment. Method of measurement: Vas score.;Dyschezia. Timepoint: At the beginning of the study, one month after the start of treatment, 6 months after the start of treatment. Method of measurement: Vas score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamaneh Esmaeili

Shahid Beheshti University of Medical Sciences

dresmaeili@gmail.com+98 21 2243 2560

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026